XML 17 R2.htm IDEA: XBRL DOCUMENT v3.24.1
Pay vs Performance Disclosure
12 Months Ended
Dec. 31, 2023
USD ($)
$ / shares
Dec. 31, 2022
USD ($)
Dec. 31, 2021
USD ($)
Dec. 31, 2020
USD ($)
Pay vs Performance Disclosure        
Pay vs Performance Disclosure, Table

Pay Versus Performance

The disclosure included in this section is prescribed by SEC rules and does not necessarily align with how the Company or the Compensation Committee view the link between the Company’s performance and named executive officer (“NEO”) pay. For additional information about our pay-for-performance philosophy and how we align executive compensation with Company performance, refer to the Compensation Discussion and Analysis beginning on page 27.

Required Tabular Disclosure of Pay Versus Performance

The amounts set forth below under the headings “Compensation Actually Paid to PEO” and “Average Compensation Actually Paid for Non-PEO NEOs” have been calculated in a manner consistent with Item 402(v) of Regulation S-K. Use of the term “compensation actually paid” (“CAP”) is required by the SEC’s rules and as a result of the calculation methodology required by the SEC, such amounts differ from compensation actually received by the individuals and the compensation decisions described in the “Compensation Discussion and Analysis” section above.

 

(a)

 

(b)

 

 

(c)

 

 

(d)

 

 

(e)

 

 

(f)

 

 

(g)

 

 

(h)

 

 

(i)

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

Value of Initial Fixed $100
Investment Based on:(4)

 

 

 

 

 

 

 

Year

 

Summary Compensation
Table Total
for PEO
($)(1)(2)

 

 

Compensation Actually Paid
to PEO
($)(3)

 

 

Average Summary Compensation Table Total for
Non-PEO NEOs
($)(1)(2)

 

 

Average Compensation Actually Paid to Non-PEO NEOs
($)(1)(2)

 

 

Total Shareholder Return
($)

 

 

NASDAQ Biotechnology Index Total Shareholder Return
($)

 

 

Net Loss
(thousands)
($)(5)

 

 

Total Revenue
(thousands)
($)(6)

 

2023

 

 

7,068,114

 

 

 

96,764

 

 

 

2,201,163

 

 

 

351,865

 

 

 

282.17

 

 

 

118.87

 

 

 

(11,938

)

 

 

198,962

 

2022

 

 

3,905,058

 

 

 

9,653,678

 

 

 

1,481,321

 

 

 

2,201,087

 

 

 

408.53

 

 

 

113.65

 

 

 

(87,400

)

 

 

99,770

 

2021

 

 

4,030,833

 

 

 

7,317,812

 

 

 

1,730,384

 

 

 

3,037,694

 

 

 

338.76

 

 

 

126.45

 

 

 

(80,926

)

 

 

75,442

 

2020

 

 

3,563,295

 

 

 

7,424,884

 

 

 

1,613,615

 

 

 

3,137,880

 

 

 

242.64

 

 

 

126.42

 

 

 

(57,240

)

 

 

65,144

 

(1)

The following individuals are our PEO and other non-PEO NEOs for each fiscal year:

Year

 

PEO

 

Non-PEO NEOs

2023

 

Michael E. Castagna

 

Steven B. Binder, Lauren M. Sabella, David B. Thomson, and Stuart A. Tross

2022

 

Michael E. Castagna

 

Steven B. Binder, Alejandro Galindo, Joseph Kocinsky, Sanjay Singh, David B. Thomson, and Stuart A. Tross

2021

 

Michael E. Castagna

 

Steven B. Binder, Joseph Kocinsky, David B. Thomson, and Stuart A. Tross

2020

 

Michael E. Castagna

 

Steven B. Binder, Joseph Kocinsky, David B. Thomson, and Stuart A. Tross

(2)

The dollar amounts reported in column (b) and (d) are the amounts of total compensation reported for Mr. Castagna (our Chief Executive Officer and PEO) and the average total compensation for our non-PEO NEOs for each corresponding year in the “Total” column of the Summary Compensation Table. Refer to “Executive Compensation—Summary Compensation Table.”

(3)

The dollar amounts reported in column (c) and (e) represent the amount of CAP to Mr. Castagna and the average amount of CAP to our Non-PEO NEOs, respectively, as computed in accordance with Item 402(v) of Regulation S-K. The dollar amounts do not reflect the actual amount of compensation earned by or paid to our NEOs during the applicable year. In accordance with the requirements of Item 402(v) of Regulation S-K, the following adjustments were made to the reported total compensation for each year to determine the CAP for the year ended December 31, 2023:

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

PEO
($)

 

 

Average Non-PEO NEOs
($)

 

Summary Compensation Table Total

 

 

7,068,114

 

 

 

2,201,163

 

Deduct: Grant Date Fair Value of "Stock Awards” Column in the Summary Compensation Table for Applicable FY

 

 

5,536,550

 

 

 

1,447,497

 

Add: Fair Value at Applicable FY End of Awards Granted during Applicable FY that Remain Unvested as of Applicable FY End (7)

 

 

3,994,631

 

 

 

1,058,886

 

Add: Year over Year Change in Fair Value of Awards Granted during Prior FY that were Outstanding and Unvested as of Applicable FY End (7)

 

 

(4,968,406

)

 

 

(1,318,753

)

Add: Vesting Date Fair Value of Awards Granted during Prior FY that Vested During Applicable FY

 

 

(461,025

)

 

 

(141,934

)

Deduct: Fair Value at Prior Year End of Awards Granted during Prior FY that were Forfeited during Applicable FY

 

 

 

 

Add: Dividends or Other Earnings Paid during Applicable FY prior to Vesting Date

 

 

 

 

CAP

 

 

96,764

 

 

 

351,865

 

 

(4)

The amounts reflect the cumulative total shareholder return of our common stock (column (f)) and the NASDAQ Biotechnology Index (column (g)) at the end of each fiscal year. In each case, assume an initial investment of $100 on December 31, 2019, and reinvestment of dividends, if any.

(5)

The dollar amounts reported in column (h) represent the net loss as reported in the Company’s audited financial statements for the applicable year.

(6)

As required by Item 402(v) of Regulation S-K, we have determined that Total Revenue is the Company-Selected Measure.

(7)

The fair values of PSUs and stock options vested during the fiscal year or outstanding as of fiscal year end were estimated using the Monte Carlo simulation model and Black-Scholes option valuation model, respectively. The following valuation assumptions used to calculate the fair values of these awards differed materially from the assumptions used to value the awards on their respective grant dates:

 

Assumptions

PSUs

 

Stock Options

Term (years)

0.38 — 2.50

 

2.00 — 6.00

Correlation Coefficient — MannKind

0.40 — 0.44

 

Correlation Coefficient — Peer Average

0.31 — 0.32

 

Correlation Coefficient — Peer Median

0.32

 

Beginning Average Stock Price

$2.95—$4.26

 

Valuation Date Stock Price

$3.64

 

$3.64 — $4.83

Initial TSR

(14.55%) — 23.39%

 

Risk-Free Rate

4.08% — 5.30%

 

Volatility — MannKind

53.85% — 61.06%

 

69.95% — 77.70%

Volatility — Peer Average

70.47% — 78.56%

 

Volatility — Peer Median

65.35% — 78.38%

 

Exercise Price

 

$1.32 — $4.55

 

     
Company Selected Measure Name Total Revenue      
Named Executive Officers, Footnote

Year

 

PEO

 

Non-PEO NEOs

2023

 

Michael E. Castagna

 

Steven B. Binder, Lauren M. Sabella, David B. Thomson, and Stuart A. Tross

2022

 

Michael E. Castagna

 

Steven B. Binder, Alejandro Galindo, Joseph Kocinsky, Sanjay Singh, David B. Thomson, and Stuart A. Tross

2021

 

Michael E. Castagna

 

Steven B. Binder, Joseph Kocinsky, David B. Thomson, and Stuart A. Tross

2020

 

Michael E. Castagna

 

Steven B. Binder, Joseph Kocinsky, David B. Thomson, and Stuart A. Tross

     
PEO Total Compensation Amount $ 7,068,114 $ 3,905,058 $ 4,030,833 $ 3,563,295
PEO Actually Paid Compensation Amount 96,764 9,653,678 7,317,812 7,424,884
Non-PEO NEO Average Total Compensation Amount 2,201,163 1,481,321 1,730,384 1,613,615
Non-PEO NEO Average Compensation Actually Paid Amount $ 351,865 2,201,087 3,037,694 3,137,880
Adjustment to Non-PEO NEO Compensation Footnote

 

 

 

 

 

 

PEO
($)

 

 

Average Non-PEO NEOs
($)

 

Summary Compensation Table Total

 

 

7,068,114

 

 

 

2,201,163

 

Deduct: Grant Date Fair Value of "Stock Awards” Column in the Summary Compensation Table for Applicable FY

 

 

5,536,550

 

 

 

1,447,497

 

Add: Fair Value at Applicable FY End of Awards Granted during Applicable FY that Remain Unvested as of Applicable FY End (7)

 

 

3,994,631

 

 

 

1,058,886

 

Add: Year over Year Change in Fair Value of Awards Granted during Prior FY that were Outstanding and Unvested as of Applicable FY End (7)

 

 

(4,968,406

)

 

 

(1,318,753

)

Add: Vesting Date Fair Value of Awards Granted during Prior FY that Vested During Applicable FY

 

 

(461,025

)

 

 

(141,934

)

Deduct: Fair Value at Prior Year End of Awards Granted during Prior FY that were Forfeited during Applicable FY

 

 

 

 

Add: Dividends or Other Earnings Paid during Applicable FY prior to Vesting Date

 

 

 

 

CAP

 

 

96,764

 

 

 

351,865

 

     
Equity Valuation Assumption Difference, Footnote

Assumptions

PSUs

 

Stock Options

Term (years)

0.38 — 2.50

 

2.00 — 6.00

Correlation Coefficient — MannKind

0.40 — 0.44

 

Correlation Coefficient — Peer Average

0.31 — 0.32

 

Correlation Coefficient — Peer Median

0.32

 

Beginning Average Stock Price

$2.95—$4.26

 

Valuation Date Stock Price

$3.64

 

$3.64 — $4.83

Initial TSR

(14.55%) — 23.39%

 

Risk-Free Rate

4.08% — 5.30%

 

Volatility — MannKind

53.85% — 61.06%

 

69.95% — 77.70%

Volatility — Peer Average

70.47% — 78.56%

 

Volatility — Peer Median

65.35% — 78.38%

 

Exercise Price

 

$1.32 — $4.55

 

     
Compensation Actually Paid vs. Total Shareholder Return

CAP vs Cumulative TSRimg30985660_6.jpg

     
Compensation Actually Paid vs. Net Income

img30985660_7.jpg 

     
Compensation Actually Paid vs. Company Selected Measure

img30985660_8.jpg 

     
Total Shareholder Return Vs Peer Group

CAP vs Cumulative TSRimg30985660_6.jpg

     
Tabular List, Table

The most important financial and non-financial performance measures used by the Company to link CAP to the Company’s NEOs for the most recently completed fiscal year to the company’s performance are set forth below. For further information regarding these performance metrics and their function in our executive compensation program, please see “Compensation Discussion and Analysis” beginning on page 27.

Total revenue;
Total shareholder return;
Deliver on Tyvaso DPI production;
Drive endocrinology business; and
Advance pipeline opportunities.
     
Total Shareholder Return Amount $ 282.17 408.53 338.76 242.64
Peer Group Total Shareholder Return Amount 118.87 113.65 126.45 126.42
Net Income (Loss) $ (11,938,000) $ (87,400,000) $ (80,926,000) $ (57,240,000)
Company Selected Measure Amount 198,962,000 99,770,000 75,442,000 65,144,000
PEO Name Michael E. Castagna Michael E. Castagna Michael E. Castagna Michael E. Castagna
Additional 402(v) Disclosure

All information provided above under the “Item 402(v) Pay Versus Performance” heading will not be deemed to be incorporated by reference into any filing of the Company under the Securities Act of 1933, as amended, or the Securities Exchange Act of 1934, as amended, whether made before or after the date hereof and irrespective of any general incorporation language in any such filing, except to the extent the Company specifically incorporates such information by reference.

     
Measure:: 1        
Pay vs Performance Disclosure        
Name Total revenue;      
Measure:: 2        
Pay vs Performance Disclosure        
Name Total shareholder return;      
Measure:: 3        
Pay vs Performance Disclosure        
Name Deliver on Tyvaso DPI production;      
Measure:: 4        
Pay vs Performance Disclosure        
Name Drive endocrinology business; and      
Measure:: 5        
Pay vs Performance Disclosure        
Name Advance pipeline opportunities.      
PSUs [Member]        
Pay vs Performance Disclosure        
Term (years), Minimum 4 months 17 days      
Term (years), Maximum 2 years 6 months      
Correlation Coefficient - MannKind, Minimum 0.4      
Correlation Coefficient - MannKind, Maximum 0.44      
Correlation Coefficient - Peer Average, Minimum 0.31      
Correlation Coefficient - Peer Average, Maximum 0.32      
Correlation Coefficient - Peer Median 0.32      
Beginning Average Stock Price, Minimum | $ / shares $ 2.95      
Beginning Average Stock Price, Maximum | $ / shares 4.26      
Valuation Date Stock Price | $ / shares $ 3.64      
Initial TSR, Minimum (14.55%)      
Initial TSR, Maximum 23.39%      
Risk-Free Rate, Minimum 4.08%      
Risk-Free Rate, Maximum 5.30%      
Volatility - MannKind, Minimum 53.85%      
Volatility - MannKind, Maximum 61.06%      
Volatility - Peer Average, Minimum 70.47%      
Volatility - Peer Average, Maximum 78.56%      
Volatility - Peer Median, Minimum 65.35%      
Volatility - Peer Median, Maximum 78.38%      
Stock Options [Member]        
Pay vs Performance Disclosure        
Term (years), Minimum 2 years      
Term (years), Maximum 6 years      
Valuation Date Stock Price, Minimum | $ / shares $ 3.64      
Valuation Date Stock Price, Maximum | $ / shares $ 4.83      
Volatility - MannKind, Minimum 69.95%      
Volatility - MannKind, Maximum 77.70%      
Exercise Price, Minimum | $ / shares $ 1.32      
Exercise Price, Maximum | $ / shares $ 4.55      
PEO        
Pay vs Performance Disclosure        
Adjustment to Compensation, Amount $ 96,764      
PEO | Stock Awards [Member]        
Pay vs Performance Disclosure        
Adjustment to Compensation, Amount 5,536,550      
PEO | Add: Fair Value at Applicable FY End of Awards Granted during Applicable FY that Remain Unvested [Member]        
Pay vs Performance Disclosure        
Adjustment to Compensation, Amount 3,994,631      
PEO | Add: Year over Year Change in Fair Value of Awards Granted during Prior FY that were Outstanding and Unvested [Member]        
Pay vs Performance Disclosure        
Adjustment to Compensation, Amount (4,968,406)      
PEO | Add: Vesting Date Fair Value of Awards Granted during Prior FY that Vested [Member]        
Pay vs Performance Disclosure        
Adjustment to Compensation, Amount (461,025)      
Non-PEO NEO        
Pay vs Performance Disclosure        
Adjustment to Compensation, Amount 351,865      
Non-PEO NEO | Stock Awards [Member]        
Pay vs Performance Disclosure        
Adjustment to Compensation, Amount 1,447,497      
Non-PEO NEO | Add: Fair Value at Applicable FY End of Awards Granted during Applicable FY that Remain Unvested [Member]        
Pay vs Performance Disclosure        
Adjustment to Compensation, Amount 1,058,886      
Non-PEO NEO | Add: Year over Year Change in Fair Value of Awards Granted during Prior FY that were Outstanding and Unvested [Member]        
Pay vs Performance Disclosure        
Adjustment to Compensation, Amount (1,318,753)      
Non-PEO NEO | Add: Vesting Date Fair Value of Awards Granted during Prior FY that Vested [Member]        
Pay vs Performance Disclosure        
Adjustment to Compensation, Amount $ (141,934)